IgA Nephropathy Clinical Trial
— PHOENIXOfficial title:
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
Verified date | February 2024 |
Source | Biogen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Patients will be enrolled in disease specific cohorts within the trial, and effectiveness of bardoxolone methyl in treating CKD will be assessed separately by cohort for each rare CKD. All patients in the study will follow the same visit and assessment schedule. Following randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, and 12, and by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will also be scheduled to be assessed at an in-person follow-up visit at Week 16, four weeks after the end of treatment.
Status | Completed |
Enrollment | 103 |
Est. completion date | January 29, 2019 |
Est. primary completion date | January 2, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Male and female patients 18 = age = 65 upon study consent; - Screening eGFR (average of Screen A and Screen B eGFR values) = 30 and = 90 mL/min/1.73 m2. The two eGFR values collected at Screen A and Screen B visits used to determine eligibility must have a percent difference = 25%; - Albumin to creatinine ratio (ACR) = 2500 mg/g at Screen B visit; - If receiving an angiotensin-converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB), patients should be prescribed the maximally tolerated labeled daily dose (MTLDD) for at least 6 weeks prior to the Screen A visit; - For patients enrolling in T1D Cohort: Diagnosis of type 1 diabetes confirmed by fasting C-peptide level. Diagnosis must have been made = 35 years of age; and prescribed stable dose of insulin to maintain adequate glucose control for at least 6 months prior to the Screen A visit; - For patients enrolling in IgAN Cohort: Biopsy-confirmed IgA nephropathy; - For patients enrolling in FSGS Cohort: Biopsy-confirmed FSGS that is not due to known secondary causes including morbid obesity, decreased renal mass, viral infections, drug-induced nephrotoxicity, or prior history of vasculitis; - For patients enrolling in ADPKD Cohort: Genetic confirmation of PKD1 mutation; - Adequate bone marrow reserve and organ function at the Screen A visit as follows: Hematologic: Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, hemoglobin (Hgb) = 9 g/dL; and Hepatic: Total bilirubin (TBL) = 1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 1.5 times ULN. Exclusion Criteria: - Kidney or any other solid organ transplant recipient or a planned transplant during the study; - B-type natriuretic peptide (BNP) level > 200 pg/mL at Screen A visit; - Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or during Screening; - Serum albumin < 3 g/dL at Screen A visit; - Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to randomization or anticipated need for immunosuppression during the study; - For patients enrolling in IgAN Cohort: Systemic manifestations of Henoch-Schonlein purpura within 1 year prior to Screen A visit; or have used belimumab, eculizumab, or rituximab within 6 months prior to Screen A visit; - For patients enrolling in ADPKD Cohort: Receiving tolvaptan; - Cerebrovascular event (stroke, transient ischemic attack) or aneurysm within 6 months prior to Screen A visit or during Screening; - History of clinically significant left-sided heart disease and/or clinically significant cardiac disease; - Uncontrolled systemic hypertension; - Systolic BP < 90 mm Hg at Screen A visit after a period of rest; - History of malignancy within 2 years prior to Screen A visit, with the exception of localized skin or cervical carcinomas; - Uncontrolled diabetes (HbA1c > 10.0%) at Screen A visit; - Untreated or uncontrolled active bacterial, fungal, or viral infection; - Participation in other interventional clinical studies within 30 days prior to Day 1; - Unwilling to practice acceptable methods of birth control (both males who have partners of child-bearing potential and females of childbearing potential) during Screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested; - Women who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
United States | Kidney Care Augusta | Augusta | Georgia |
United States | Research Management, Inc. | Austin | Texas |
United States | Northeast Clinical Research Center, LLC | Bethlehem | Pennsylvania |
United States | University of Alabama Birmingham | Birmingham | Alabama |
United States | Tufts Medical Center - Division of Nephrology Tufts Medical Center | Boston | Massachusetts |
United States | Jacobi Medical Center | Bronx | New York |
United States | Boise Kidney & Hypertension, PLLC | Caldwell | Idaho |
United States | Nephrology Associates | Chattanooga | Tennessee |
United States | Gulfcoast Endocrine and Diabetes Center | Clearwater | Florida |
United States | Remington-Davis Clinical Research | Columbus | Ohio |
United States | Renal Disease Research Intitute | Dallas | Texas |
United States | Denver Nephrology | Denver | Colorado |
United States | Research By Design | Evergreen Park | Illinois |
United States | Mendez Center for Clinical Research LLC | Fairfax Station | Virginia |
United States | Larry Stonesifer, M.D. | Federal Way | Washington |
United States | Physician's East Endocrine Research | Greenville | North Carolina |
United States | Clinical Research Consultants, LLC | Kansas City | Missouri |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | South Florida Research Institute | Lauderdale Lakes | Florida |
United States | University of California Los Angeles | Los Angeles | California |
United States | Boise Kidney & Hypertension, PLLC | Meridian | Idaho |
United States | Columbia University Medical Center - Nephrology | New York | New York |
United States | Four Rivers Clinical Research, Inc | Paducah | Kentucky |
United States | Phoenician Centers for Research & Innovation (PCRI) | Phoenix | Arizona |
United States | Coastal Nephrology Associates | Port Charlotte | Florida |
United States | The Warren Alpert School of Brown University | Providence | Rhode Island |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Renal Associates, PA | San Antonio | Texas |
United States | Northwest Louisiana Nephrology | Shreveport | Louisiana |
United States | Advanced Clinical Research | West Jordan | Utah |
Lead Sponsor | Collaborator |
---|---|
Reata, a wholly owned subsidiary of Biogen |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 | To assess the change in eGFR from baseline to week 12. eGFR is a measure of kidney function assessed through blood/serum. Higher eGFRs represent better/improved kidney function. Lower eGFRs represent poorer/decreased kidney function. | 12 weeks after participant receives the first dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016323 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
|
Phase 2 | |
Withdrawn |
NCT02433236 -
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT02231125 -
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
|
Phase 4 | |
Completed |
NCT01502579 -
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
|
N/A | |
Not yet recruiting |
NCT01203007 -
Diet Intervention in Food Sensitive Patients With IgA Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00657059 -
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
|
Phase 3 | |
Recruiting |
NCT04684745 -
Open-Label Extension Study of BION-1301 in IgA Nephropathy
|
Phase 2 | |
Completed |
NCT03719443 -
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02112838 -
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
|
Phase 2 | |
Withdrawn |
NCT02052219 -
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
|
Phase 3 | |
Completed |
NCT00767221 -
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
|
Phase 2 | |
Recruiting |
NCT04438603 -
The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Terminated |
NCT04905212 -
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
|
Phase 2 | |
Terminated |
NCT04042623 -
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT03633864 -
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
|
Phase 2 | |
Not yet recruiting |
NCT06454110 -
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
|
Phase 2 | |
Recruiting |
NCT02954419 -
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
|
||
Recruiting |
NCT03001947 -
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
|